Valuation: Personalis, Inc.

Market Cap 182.2Cr 156.15Cr 146.08Cr 133.55Cr 252.02Cr 17TCr 254.7Cr 1.73TCr 672.12Cr 8.76TCr 684.11Cr 669.3Cr 29TCr P/E 2026 *
-15.6x
P/E 2027 * -18.1x
Enterprise Value 164.44Cr 140.93Cr 131.84Cr 120.53Cr 227.45Cr 16TCr 229.87Cr 1.56TCr 606.6Cr 7.91TCr 617.42Cr 604.06Cr 26TCr EV / Sales 2026 *
19.9x
EV / Sales 2027 * 15.7x
Free-Float
73.85%
Yield 2026 *
-
Yield 2027 * -
1 day-7.18%
1 week+22.82%
Current month+34.76%
1 month+44.82%
3 months+101.42%
6 months+105.79%
Current year+114.32%
1 week 14.42
Extreme 14.42
18.89
1 month 11.52
Extreme 11.52
18.89
Current year 4.96
Extreme 4.955
18.89
1 year 4.65
Extreme 4.6524
18.89
3 years 0.89
Extreme 0.8906
18.89
5 years 0.89
Extreme 0.8906
23.04
10 years 0.89
Extreme 0.8906
53.46
Manager TitleAgeSince
Chief Executive Officer 57 02/03/2023
Chief Executive Officer 65 31/12/2022
President 55 13/03/2026
Director TitleAgeSince
Director/Board Member 79 01/05/2019
Chairman 76 17/05/2022
Director/Board Member 72 06/03/2021
Date Insider Type Main position Quantity % Market Cap.
15/07/26 Fiscal year

Chairperson

3,00,000 0.2865%
09/07/26 Fiscal year

Chief Executive Officer

3,00,000 0.2865%
29/06/26 Fiscal year

Chief Financial Officer

14,946 0.0143%
Change 5-day change 1-year change 3-year change Capi.($)
-7.18%+22.82%+253.21%+1,007.79% 182.2Cr
+0.82%+4.67%+3.39%+25.12% 5.12TCr
+1.01%-0.20%+471.68%+564.93% 4.53TCr
+0.16%+7.88%+36.14%+20.76% 4.28TCr
-0.66%+2.61%+18.59%+87.04% 4.23TCr
+0.88%-3.48%+17.20%+53.83% 3.22TCr
-0.12%+3.84%+33.73%+145.25% 1.73TCr
-0.53%+1.84% - - 1.65TCr
+0.22%+5.31%+9.92%+31.33% 1.48TCr
+1.15%+4.17%+84.49%+50.33% 1.43TCr
Average -0.43%+5.19%+103.15%+220.71% 2.79TCr
Weighted average by Cap. +0.32%+3.20%+102.45%+147.82%

Financials

2026 *2027 *
Net sales 8.25Cr 7.07Cr 6.61Cr 6.04Cr 11Cr 789.64Cr 12Cr 78Cr 30Cr 396.51Cr 31Cr 30Cr 1.31TCr 11Cr 9.44Cr 8.84Cr 8.08Cr 15Cr 1.06TCr 15Cr 104.55Cr 41Cr 529.86Cr 41Cr 40Cr 1.75TCr
Net income -12Cr -9.86Cr -9.23Cr -8.44Cr -16Cr -1.1TCr -16Cr -109.19Cr -42Cr -553.4Cr -43Cr -42Cr -1.83TCr -10Cr -8.74Cr -8.17Cr -7.47Cr -14Cr -976.21Cr -14Cr -97Cr -38Cr -490.19Cr -38Cr -37Cr -1.62TCr
Net Debt -18Cr -15Cr -14Cr -13Cr -25Cr -1.7TCr -25Cr -168.49Cr -66Cr -853.92Cr -67Cr -65Cr -2.83TCr -9.1Cr -7.8Cr -7.3Cr -6.67Cr -13Cr -871.73Cr -13Cr -86Cr -34Cr -437.73Cr -34Cr -33Cr -1.45TCr
Logo Personalis, Inc.
Personalis, Inc. is engaged in developing, marketing and selling advanced cancer genomic tests and analytics. The Company’s advanced genomic sequencing and analytics support the development of personalized cancer vaccines and other cancer immunotherapies. Its products include NeXT Personal, ImmunoI DNeXT, NeXT Personal Dx, NeXT Dx, whole exome sequencing (WES), and whole genome sequencing (WGS). NeXT Personal is a tumor-informed liquid biopsy test for the detection of minimal residual disease (MRD) and recurrence in cancer. NeXT Dx is a comprehensive tumor profiling test that is used to help select therapy for a cancer patient and identify potential clinical trials for a patient. The Company performed WGS on human samples for research projects, such as population sequencing initiatives. The Company’s tests and analytics are used by pharmaceutical companies for translational research, biomarker discovery, and the development of personalized cancer therapies.
Employees
260
Date Price Change Volume
24/26/24 $17.06 -7.18% 47,93,048
21/26/21 $18.38 +8.89% 80,01,823
20/26/20 $16.88 +6.77% 1,42,08,491
19/26/19 $15.81 +13.66% 82,79,946
18/26/18 $13.91 +0.14% 10,25,379
Trader
Investor
-
Global
-
Quality
-
ESG MSCI
A
Sell
Consensus
Buy
Mean consensus
OUTPERFORM
Number of Analysts
5
Last Close Price
17.06USD
Average target price
15.44USD
Spread / Average Target
-9.51%

Quarterly revenue - Rate of surprise

  1. Stock Market
  2. Stocks
  3. PSNL Stock